Cytosin-Arabinosid

Bortezomib

Zhongnan HospitalPhase 1Dormant

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Bortezomib cohort.

Asset / Sponsor	Phase	Rating
FILGRASTIM Zhongnan Hospital	Phase 2	B
Inno-206 Zhongnan Hospital	Phase 2	B
Bortezomib Zhongnan Hospital	Phase 2	B
DEXAMETHASONE Beijing Chao Yang Hospital	Phase 2	CCC
Cyclophosphamide Beijing Chao Yang Hospital	Phase 2	CCC
PREDNISONE TABLETS Beijing Chao Yang Hospital	Phase 2	CCC

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative ·

82 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.